Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Clin Cancer Res. 2022 May 2;28(9):1863–1870. doi: 10.1158/1078-0432.CCR-21-3018

Figure 1: Real-world overall survival stratified by RSPO/RNF43 status.

Figure 1:

A) Comparison of RSPOfp vs. RNF43/RSPOfp-WT patients (RSPOfp vs. WT: HR 0.62, 95%CI 0.48–0.81, p<0.001).

B) Comparison of RNF43-mut vs. RNF43/RSPOfp-WT patients (HR 0.86, 95%CI 0.78–0.94, p<0.001).